CVRx Inc (NASDAQ: CVRX) announced that Devoted Health has issued a Medicare Advantage coverage policy for its Barostim therapy. The policy becomes effective on July 17, 2026.

Devoted Health is a national health insurance company with the eighth largest Medicare Advantage enrollment in the U.S. The insurer provides coverage to approximately 466,000 Medicare Advantage members across 29 states.

Coverage Scope and Market Impact

The new policy covers Barostim for patients meeting its current FDA-approved indication. It also extends coverage to patients enrolled in the BENEFIT-HF trial. This landmark heart failure study evaluates Barostim in a significantly expanded patient population initiated earlier this year.

Kevin Hykes, President and Chief Executive Officer of CVRx, stated that Devoted Health is one of the fastest-growing Medicare Advantage plans in the U.S. He noted that the combined Devoted Health and Humana coverage policies represent approximately 21 percent of Medicare Advantage enrollment.

Reimbursement Progression

The Devoted Health policy follows several reimbursement developments for Barostim in 2026:

• In January, Category I CPT codes went into effect for the Barostim procedure.
• The Centers for Medicare & Medicaid Services (CMS) approved Category B IDE coverage for patients enrolled in the BENEFIT-HF trial.
• In May, Humana issued a Barostim therapy coverage policy for Medicare Advantage members and patients enrolled in the BENEFIT-HF trial.

What the Numbers Show

The consolidation of coverage among major payers indicates a shift toward standardized reimbursement for neuromodulation therapies. With Devoted Health and Humana covering approximately 21 percent of the Medicare Advantage market, CVRx has secured access to a significant portion of its potential patient base without relying solely on traditional fee-for-service models.

About CVRx

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim is the first medical technology approved by the FDA that uses neuromodulation to improve symptoms of patients with heart failure.

Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. It holds FDA Breakthrough Device designation and CE Mark approval for heart failure and resistant hypertension in the European Economic Area.

Law firm Hagens Berman has launched an investigation into CVRx, Inc. (NASDAQ: CVRX) for potential violations of federal securities laws, adding to the legal scrutiny already initiated by Block & Leviton. The new probe follows a 59% collapse in the company’s stock price on August 7, 2026, and focuses on allegations that CVRx misled investors about the severity of its operational crises and regulatory liabilities.

The investigation centers on three critical developments disclosed or occurring in August 2026: a civil investigative demand from the U.S. Department of Justice, a significant cut to full-year revenue guidance, and the abrupt termination of Chief Revenue Officer Robert John on August 10, 2026. Hagens Berman partner Reed Kathrein stated the firm is examining whether there is a direct connection between the DOJ inquiry and the CRO’s departure, as well as whether the true state of the commercial sales force and Medicare Advantage reimbursement rates were obscured from shareholders.

Escalating Legal and Operational Pressures

CVRx’s sole commercial product, Barostim, is an FDA-approved implantable neuromodulation device for heart failure patients. Historically, the company assured investors that its growth strategy was anchored by a completed sales force transformation and high approval rates from Medicare Advantage payers, citing a "$10.5 billion market opportunity" with less than 1% penetration.

However, disclosures made after market close on August 6, 2026, revealed severe headwinds:

• DOJ Civil Investigative Demand: On May 14, 2026, CVRx received a CID from the U.S. Department of Justice. The investigation examines whether the company caused the submission of false claims to government health programs by improperly marketing Barostim, paying kickbacks to healthcare providers, or submitting false information.
• Medicare Advantage Approval Collapse: The company revealed that its primary Medicare Advantage payer, which historically approved 80% of prior authorizations within 30 days, increased initial denials. Consequently, 30-day approvals dropped to just 25%.
• Sales Force Deterioration: CVRx reported sequentially flat growth in sales territories, high turnover, and strained onboarding processes, leading to the decision to lower its financial outlook.

Financial Guidance and Market Reaction

The catalyst for the initial legal scrutiny by Block & Leviton was CVRx’s announcement on August 6, 2026, that it was lowering its full-year revenue guidance to $58–60 million from a previous range of $63–67 million. The company attributed this miss to internal operational strains, specifically noting that rapid sales-force hiring had overwhelmed onboarding and training processes. This resulted in elevated turnover and slower productivity ramps for new territory managers, with nearly half of its regions reporting negative year-to-date implant growth.

Beyond internal issues, CVRx cited prolonged reimbursement challenges with one of its largest Medicare Advantage payers. The divergence between the prior and revised guidance highlights the severity of the execution gap, representing a potential loss of up to $9 million in expected annual revenue at the lower end of the prior estimate.

What the Numbers Show

The sharp contraction in revenue guidance coincides with a dramatic deterioration in reimbursement efficiency. The drop in Medicare Advantage approval rates from 80% to 25% within 30 days suggests a structural breakdown in the company’s primary revenue channel, rather than a temporary delay. This operational failure directly correlates with the $9 million downward revision in annual revenue expectations, indicating that the sales force instability and payer pushback have materially impaired top-line performance.

Investor Eligibility and Next Steps

Investors who purchased CVRx, Inc. common stock and experienced losses may be eligible to participate in potential class action lawsuits led by either firm. Eligibility extends to those who have not yet sold their investments. Both Block & Leviton and Hagens Berman have invited individuals with non-public information to contact them regarding the SEC whistleblower program, where rewards can reach up to 30% of successful recoveries.